HAP score as prognostic factor of hepatocellular carcinoma treated with transarterial chemoembolization in a Latin American center

Autores/as

  • Estefanía Liza Baca Department of the Digestive System, Edgardo Rebagliati Martins National Hospital, EsSalud. Lima, Peru.
  • Javier Díaz Ferrer Department of the Digestive System, Edgardo Rebagliati Martins National Hospital, EsSalud. Lima, Peru.

DOI:

https://doi.org/10.47892/rgp.2018.382.893

Palabras clave:

Carcinoma, hepatocellular, Liver cirrhosis, Chemoembolization, therapeutic, Prognosis

Resumen

Introduction: Hepatocellular carcinoma (HCC) in cirrhosis is diagnosed, most of times, when it is not susceptible to curative treatment. Transarterial chemoembolization (TACE) is a palliative therapeutic option with heterogeneous results. The HAP score stratifies patients who will benefit from the first TACE. Objective: To evaluate if the HAP score is a prognostic factor of HCC treated with TACE. Materials and methods: Retrospective cohort study in cirrhotic patients with HCC and first TACE at the Edgardo Rebagliati Martins National Hospital, Lima-Peru, from June 2011 to June 20139. The HAP score was applied, mortality and survival were observed with a follow-up of 36 months. Results: We included 54 patients with age of 67.7±9.9 years, 59.3% Child-Pugh A and 40.7% Child-Pugh B, MELD score of 11±2.7; 51.9 and 40.7% were BCLC A and B, respectively; 66.7% had a single tumor and 70.4% had a predominant tumor <5cm. The HAP score classified 8, 14, 26 and 6 patients as HAP A, B, C and D, respectively. The overall survival was 19.5±11.2 months and 32.8±6.5 months for HAP A, 24.9±14.8 months for HAP B, 13.9±5.2 months for HAP C and 4±6.6 months for HAP D. There were no deaths at 12 months in HAP A. At 24 months, mortality for HAP C and D was 100%. At 36 months, the survival rate for HAP A and B was 75 and 42.9%, respectively. Conclusions: The HAP score is a useful tool to guide the management decisions of cirrhotic patients with HCC requiring TACE due to its value in predicting mortality and survival.

Descargas

Los datos de descargas todavía no están disponibles.

Métricas

Cargando métricas ...

Descargas

Publicado

10.08.2018

Cómo citar

1.
Liza Baca E, Díaz Ferrer J. HAP score as prognostic factor of hepatocellular carcinoma treated with transarterial chemoembolization in a Latin American center. Rev Gastroenterol Peru [nternet]. 10 de agosto de 2018 [citado 20 de abril de 2024];38(2):164-8. isponible en: https://revistagastroperu.com/index.php/rgp/article/view/893

Número

Sección

ARTÍCULOS ORIGINALES

Artículos más leídos del mismo autor/a